Nitric oxide synthase inhibitor reduces airway inflammation in mouse models with asthma

doi:10.16352/j.issn.1001-6325.2023.03.462

Abstract

Abstract: Objective To explore the therapeutic effect of nitric oxide synthase (NOS) inhibitor in asthmatic mice. Methods BALB/c mice of 5 to 6 weeks were randomly divided into five groups with 10 in each: 1)control group; 2)asthma group: The asthma model was established by ovalbumin (OVA)-sensitized mice; 3)S-methyl isothiourea sulfate (SMT) group: OVA-sensitized asthmatic mice were stimulated and then given with SMT; 4)N-nitro-L-arginine methyl ester (L-NAME) group: OVA-sensitized asthmatic mice were stimulated and then given with L-NAME; 5) NG-monomethyl-L-arginine (L-NMMA) group: OVA-sensitized asthmatic mice were stimulated and then given with L-NMMA. HE staining was used for histopathological analysis. Airway reactivity was assessed using a methacholine challenge test. The levels of nitric oxide (NO) and cytokines in serum and bronchoalveolar lavage fluid(BALF) were detected by ELISA. Results Compared with the control group, goblet cell proliferation and increased mucus secretion were found in the asthma group, together with a large number of inflammatory cell infiltration around the trachea and blood vessels and significantly increased airway resistance, which were improved after the administration of NOS inhibitors, especially in the SMT group. Compared with the control group, the levels of NO in plasma, BALF and lung tissue homogenate were significantly increased in the asthma group (P＜0.05), while the level of IL-2, IL-4, IL-17 and TNF-α in plasma and BALF was significantly increased (P＜0.05). Compared with the asthma group, the level of NO in plasma, BALF and lung tissue homogenate was significantly decreased in SMT group (P＜0.05), while the level of IL-2, IL-4, IL-17 and TNF-α in plasma and BALF was significantly decreased in SMT group (P＜0.05). Compared with the asthma group, the level of plasma NO, IL-2, IL-17, and TNF-α in the L-NAME group was significantly decreased (P＜0.05). The level of NO, IL-2, IL-17, and TNF-α in BALF was significantly decreased (P＜0.05). Compared with the asthma group, the plasma level of NO, IL-2, IL-4, IL-17 and TNF-α in the L-NMMA group was significantly decreased (P＜0.05). The level of NO, IL-2, IL-4, IL-17 and TNF-α in BALF was significantly decreased(P＜0.05), and the level of NO in lung tissue homogenate was significantly decreased (P＜0.05). Conclusions NOS inhibitor, especially SMT may reduce airway inflammation of asthmatic mice.

Key words: asthma, nitric oxide, nitric oxide synthase, inhibitor

CLC Number:

R726.1

WANG Fei, LI Wenxuan, DING Junqiong, LIU Zhen, WANG Xiaoming, YANG Ju, WANG Dalian. Nitric oxide synthase inhibitor reduces airway inflammation in mouse models with asthma[J]. Basic & Clinical Medicine, 2023, 43(3): 462-467.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/10.16352/j.issn.1001-6325.2023.03.462

http://journal11.magtechjournal.com/Jwk_jcyxylc/EN/Y2023/V43/I3/462

References

[1]Abdo W, Haziri I, Dmerdash M, et al. Anatabine attenuates ovalbumin-induced asthma via oxidative stress and inflammation mitigation and Nrf2/HO-1 signaling upregula-tion in rats[J]. Life Sciences, 2022,308:120954. doi: 10.1016/j.lfs.2022.120954.
[2]Habib N, Pasha MA, Tang DD. Current understanding of asthma pathogenesis and biomarkers?[J].Cells, 2022, 11:2764. doi: 10.3390/cells11172764.
[3]Manda-Handzlik A, Bystrzycka W, Cieloch A, et al. Nitric oxide and peroxynitrite trigger and enhance release of neutrophil extracellular traps[J]. Cell Mol Life Sci, 2020, 77: 3059-3075.
[4]Nowakowska J, Sobkowiak P, Bręborowicz A, et al. Nitric oxide synthase 2 promoter polymorphism is a risk factor for allergic asthma in children[J]. Medicina (Kaunas), 2021, 57: 1341. doi:10.3390/medicina57121341.
[5]黄华,周龙,姚迪,等. LncRNA PVT1通过调节miR-214/STAT6轴减轻哮喘模型小鼠气道炎性反应[J]. 基础医学与临床, 2022, 42: 1374-1380.
[6]Weng Q, Zhu C, Zheng K, et al. Early recruited neutrophils promote asthmatic inflammation exacerbation by release of neutrophil elastase[J]. Cell Immunol, 2020, 352: 104101. doi: 10.1016/j.cellimm.2020.104101.
[7]Custovic A, Siddiqui S, Saglani S. Considering bio-markers in asthma disease severity[J]. J Allergy Clin Immunol, 2022, 149: 480-487.
[8]Sadaf S, Singh AK, Awasthi D, et al. Augmentation of iNOS expression in myeloid progenitor cells expedites neutrophil differentiation[J].J Leukoc Biol, 2019, 106: 397-412.
[9]Moncada S, Higgs A, Furchgott R. International union of pharmacology nomenclature in nitric oxide research[J]. Pharmacol Rev. 1997, 49: 137-142.
[10]Singh D, Richards D, Knowles RG, et al. Selective inducible nitric oxide synthase inhibition has no effect on allergen challenge in asthma[J]. Am J Respir Crit Care Med, 2007, 176: 988-993.
[11]Bayarri MA, Milara J, Estornut C, et al. Nitric oxide system and bronchial epithelium: more than a barrier[J]. Front Physiol, 2021, 12: 687381. doi: 10.3389/fphys.2021.687381.
[12]Dao VT, Elbatreek MH, Fuchβ T, et al. Nitric oxide synthase inhibitors into the clinic at last[J]. Handb Exp Pharmacol,2021, 264: 169-204.

[1]	QU Dapeng, SUN Huiyan, LI Qiang, WANG Hongquan. Recent progress of the role of ferroptosis in the pathogenesis of early brain injury after subarachnoid hemorrhage [J]. Basic & Clinical Medicine, 2023, 43(3): 486-489.
[2]	LIU Fen, HU Runfang, MAO Song, XU Min, SHI Wenjing, CHEN Ling. Dexamethasone attenuates airway inflammation in mouse models with allergic asthma [J]. Basic & Clinical Medicine, 2023, 43(3): 402-407.
[3]	DAI Zhixin, WANG Yumin. Progress on the role of NLRP3 inflammasome in hyperuricemic nephropathy [J]. Basic & Clinical Medicine, 2023, 43(2): 322-326.
[4]	FANG Siyin, LIU Chen, WU Jinhui. Research progress on the mechanism of microtubule inhibitors in vascular neoplastic diseases [J]. Basic & Clinical Medicine, 2023, 43(2): 327-331.
[5]	WANG Ping, XU Zuo-jun, XU Kai-feng. Tuberous sclerosis complex as a rare cause of multiple nodular and cystic lung disease:a case report [J]. Basic & Clinical Medicine, 2022, 42(9): 1424-1427.
[6]	HUANG Hua, ZHOU Long, YAO Di, XU Yi. LncRNA PVT1 alleviates inflammation of airway via regulating miR-214/STAT6 axis in mouse models with asthma [J]. Basic & Clinical Medicine, 2022, 42(9): 1374-1380.
[7]	HU Bao-li, HU Bin. Research progress on roxadustat treatment for renal anemia [J]. Basic & Clinical Medicine, 2022, 42(9): 1449-1453.
[8]	GAN Zi-ying, TANG Hui. Research progress of oncolytic virus combined with PD-1/PD-L1 inhibitors [J]. Basic & Clinical Medicine, 2022, 42(4): 651-655.
[9]	TANG Li-ping, YAN Jin, FAN Fang, WANG Hao, HUANG Na. Cordycepin inhibits bronchial epithelial-mesenchymal transition in asthmatic rats [J]. Basic & Clinical Medicine, 2022, 42(4): 607-615.
[10]	BAO Min, LIN Mei, ZHEN Hai-ning, HE Fang, DING Min, YUAN Zhu-qing, CHEN Ya-jun, XUE Xin-xin. Aldose reductase inhibitors inhibit the oxidative stress response of human bronchial epithelial cell line BEAS-2 induced by house dust mite [J]. Basic & Clinical Medicine, 2022, 42(4): 616-621.
[11]	SI Xiao-yan, WANG Han-ping, ZHANG Li, WANG Meng-zhao, ZHANG Xiao-tong. Cytokine release syndrome caused by immune checkpoint inhibitor: a case report [J]. Basic & Clinical Medicine, 2022, 42(11): 1764-1766.
[12]	SHAO Zhi-ding, GAO Xue, REN Jing, TANG Xiao-lei. Screening aptamers for 5-hydroxytryptamine receptor and its anti-depressant function [J]. Basic & Clinical Medicine, 2022, 42(10): 1514-1521.
[13]	CHEN Sheng, WANG Chun-ming, YAN Xue-fei, MAO Yuan-qing. Specific necroptosis inhibitor-1(Nec-1) attenuates glial scar formation in rat models with spinal cord injury [J]. Basic & Clinical Medicine, 2022, 42(1): 94-99.
[14]	LI Yang-fang, HU Hui-min. PTTG and p21 as prognostic biomarker in radiotherapy for non-functional pituitary adenomas [J]. Basic & Clinical Medicine, 2021, 41(9): 1253-1259.
[15]	ZHANG Ruo-xi, HAN Bing. Progress of immune checkpoint inhibitors for the treatment of myelodysplastic syndrome [J]. Basic & Clinical Medicine, 2021, 41(8): 1210-1215.